FRMS CO., LTD(SZ:300049)2022-12-08 08:10Sales Performance - The overall sales of the Fibroscan diagnostic device are within expected ranges, with satisfactory performance noted, particularly in the U.S. market, which is expected to show growth this year [2][3]. - The domestic sales strategy primarily employs an agency model, while international sales in Western Europe mostly utilize a direct sales model [3]. Market and Competition - The main competitors in the market are two companies: Wuxi Haike and Shenzhen Yiti Medical [2][3]. - The company does not aim to eliminate all competitors, as a healthy and orderly market environment is beneficial for industry development [2]. Product Development and Strategy - The company has established 37 "Love Liver" centers, which are still in the early stages and are not expected to have a significant impact on profits in the short term [3]. - The future sales strategy for devices will depend on market conditions, with considerations for both direct sales and free placements to achieve subsequent revenue [3][4]. Financial Outlook - The company is confident in achieving its annual profit targets, driven by three main factors: improved gross margins from reduced cordyceps prices, increased device sales, and higher sales of "Love Liver" products [5]. - The current sales volume of traditional devices (502 model) accounts for over 50%, with the newer Touch model gaining market share [5]. Future Vision - In three years, the company aims to provide comprehensive solutions for liver disease patients, including more medical tools, complete medication needs, and a nationwide network of management centers [6].